Advanced searches left 3/3

Acute Promyelocytic Leukemia - PubMed

Summarized by Plex Scholar
Last Updated: 04 September 2022

* If you want to update the article please login/register

The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.

We conducted a three-institution retrospective review with the aim of determining the role of short-term adjuvant chemotherapy in treating moderate DS in patients with low- or intermediate risk APLs who were originally treated with ATRA/ATO only protocols. We investigated the difference in the incidence and duration of moderate DS in APL patients treated with ATRA/ATO with or without adjuvant chemotherapy. Patients with low- or intermediate risk APL patients were retrospectively identified and included in this study; 36 patients under ATRA/ATO/induction therapy; 21 patients under ATRA/Adjuvant chemotherapy combination induction therapy; and 21 patients were retrospectively identified and included in this research; 36 patients under ATRA/ATO only induction therapy; 36 patients under ATRA/ATO only induction therapy; and 21 patients received ATRA/ATO/adjuvant chemotherapy combination induction therapy In patients receiving combined therapy, the median duration of DS resolution in patients receiving ATRA/ATO was 17 days, only, and in patients receiving combination therapy were 8 days. In conclusion, adding adjuvant chemotherapy to ATRA/ATO only protocol may reduce the risk of DS and hospital stay in APL induction therapy.

Source link: https://doi.org/10.3389/fonc.2022.911745


Treatment for relapsed acute promyelocytic leukemia.

When patients achieve molecular CR, autologous hematopoietic cell transplantation is considered the postremission therapy of choice, according to recent reports, although recent research has shown that autologous CR is not necessary for autologous HCT's success. To improve the therapy for patients with relapsed APL, it is essential to collect clinical data of patients who have recovered after the ATRA + ATO frontline therapy within the framework of national and international cooperation.

Source link: https://doi.org/10.1007/s00277-022-04954-0

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions